Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-017-0620-7
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9… read more here.
Keywords: clinical pharmacokinetics; evolocumab pcsk9; ldl; pharmacokinetics pharmacodynamics ... See more keywords